MLYS
Mineralys Therapeutics, Inc.
$28.21
-0.06
(-0.21%)
Mkt Cap
2.49B
Volume
642,963
52W Range
22.3-47.65
Sector
Healthcare
Beta
0.68
EPS (TTM)
-4.24 USD
P/E Ratio
-15.85
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (154.65M) | (177.81M) | (71.90M) | (29.80M) | (19.41M) | (3.43M) |
| EPS | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 | -0.74 |
| Free Cash Flow | (142.43M) | (166.41M) | (81.17M) | (29.22M) | (14.56M) | (2.46M) |
| FCF / Share | -2.11 | -3.43 | -2.24 | -5.66 | -2.92 | -0.53 |
| Operating CF | (142.42M) | (166.31M) | (81.17M) | (29.22M) | (14.56M) | (2.46M) |
| Total Assets | 661.81M | 205.90M | 251.64M | 114.44M | 11.12M | 1.49M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 4.50M |
| Cash & Equiv | 172.92M | 114.09M | 49.30M | 87.70M | 10.61M | 1.41M |
| Book Value | 646.69M | 191.26M | 241.15M | (52.27M) | (22.93M) | (3.60M) |
| Return on Equity | -0.24 | -0.93 | -0.30 | N/A | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (241.07M) | (39.34M) | (32.23M) | (36.93M) | (43.27M) | (42.21M) | (48.95M) | (56.34M) | (41.01M) | (31.51M) | (24.39M) | (22.76M) |
| EPS | -2.85 | -0.47 | -0.40 | -0.52 | -0.66 | -0.79 | -0.98 | -1.13 | -0.83 | -0.70 | -0.61 | -0.57 |
| Free Cash Flow | (32.56M) | (39.47M) | (37.90M) | (28.87M) | (30.17M) | (45.49M) | (66.84M) | (50.22M) | (30.15M) | (19.20M) | (28.98M) | (19.03M) |
| FCF / Share | -0.38 | -0.48 | -0.47 | -0.41 | -0.46 | -0.86 | -1.34 | -1.01 | -0.61 | -0.43 | -0.72 | -0.48 |
| Operating CF | (32.56M) | (39.47M) | (37.89M) | (28.87M) | (30.17M) | (45.49M) | (66.84M) | (50.19M) | (30.15M) | (19.14M) | (28.98M) | (19.03M) |
| Total Assets | 667.85M | 652.86M | 661.81M | 599.95M | 335.72M | 354.94M | 205.90M | 268.25M | 318.49M | 347.25M | 251.64M | 277.56M |
| Total Debt | 97.62M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 138.27M | 112.78M | 172.92M | 217.60M | 101.79M | 165.01M | 114.09M | 97.27M | 67.86M | 90.42M | 49.30M | 86.30M |
| Book Value | 550.92M | 638.14M | 646.69M | 576.43M | 313.55M | 341.56M | 191.26M | 236.93M | 290.10M | 328.05M | 241.15M | 264.01M |
| Return on Equity | -0.44 | -0.06 | -0.05 | -0.06 | -0.14 | -0.12 | -0.26 | -0.24 | -0.14 | -0.10 | -0.10 | -0.09 |
MLYS News
Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision
Canada Pension Plan Investment Board Buys New Holdings in Mineralys Therapeutics, Inc. $MLYS
BlackRock Inc. Buys New Position in Mineralys Therapeutics, Inc. $MLYS
Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript
Mineralys Therapeutics Q2 Earnings Call Highlights
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision